Extended Release Amantadine Provides 3.4 More Hours of ON Time Daily in Parkinson Disease 

  • Movement disorders
  • Parkinson disease

A new post-hoc analysis of pivotal trial data shows extended-release amantadine (Gocovri; Adamas Pharmaceuticals, Emeryville, CA) decreased dyskinesia and OFF time for individuals with Parkinson Disease (PD). Extended-release amantadine is indicated for the treatment of dyskinesia in people with Parkinson's disease receiving levodopa-based therapy. 

In this pooled retrospective data analysis, participants in the trial who experienced more than 2.5 hours of OFF time and at least 1 hour of troublesome dyskinesia a day (n=101) were evaluated. In this subgroup had treatment with extended-release amantadine provided an improvement of 3.4 hours per day in good ON time compared with placebo. This improvement in good ON time was owing to a reduction in the number of hours spent in OFF as well as the hours spent ON with troublesome dyskinesia. In addition to increasing good ON time, patient-reported assessments showed extended-release amantadine demonstrated significant improvements in the effects of their symptoms on daily activities and provided more continuous ON time without interruptions from OFF and dyskinesia episodes.

“This presentation aims to provide additional insights on the effect of Gocovri in reducing OFF time for patients with Parkinson disease,” said Robert A. Hauser MD, MBA, professor of Neurology, director, USF Parkinson Disease and Movement Disorders Center Parkinson Foundation Center of Excellence, and lead author of the presentation. “For clinicians seeking to improve management of OFF and dyskinesia for patients without adjusting levodopa doses, these results suggest Gocovri could be an important treatment option.”

“It is our hope at Adamas that patients will not have to make the difficult decision between reducing OFF time or troublesome dyskinesia,” said Jean Hubble MD, vice president, Medical Affairs at Adamas. “I am encouraged these results show Gocovri can lead to increased good ON time, giving patients the opportunity to spend time with family and friends with fewer disruptions and more sustained good ON time.”

This data is presented as Poster  3387 on the 2020 AAN Science Highlights Platform. 

Dopamine Improves Cognitive Function in Mild-to-Moderate Alzheimer Disease

Previous News Article

Phase 3 Clinical Trial for Antiamyloid Beta Treatment of Preclinical Alzheimer Disease Initiated 

Next News Article
This Month's Issue
Stiff-Person Syndrome

Jakai D. Nolan, DO, MPH, and Jacqueline A. Nicholas, MD, MPH

Epilepsy Essentials: EEG Findings Associated With COVID-19

Michelle L. Dougherty, MD, FAES, FAAN